Alerts will be sent to your verified email
Verify Email
ALIVUS
|
Alivus Life Sciences
|
Neuland Laboratories
|
IOL Chem & Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
25.27 % | 14.95 % | 8.9 % |
|
5yr Avg Net Profit Margin
|
20.19 % | 13.18 % | 6.28 % |
|
Price to Book
|
4.08 | 11.27 | 1.62 |
|
P/E
|
23.19 | 97.59 | 26.03 |
|
5yr Avg Cash Conversion Cycle
|
100.66 Days | 38.21 Days | 37.81 Days |
|
5yr Average Interest Coverage Ratio
|
371.82 | 20.78 | 15.8 |
|
5yr Avg ROCE
|
33.88 % | 17.63 % | 12.63 % |
|
5yr Avg Operating Profit Margin
|
29.64 % | 21.01 % | 10.64 % |
|
5 yr average Debt to Equity
|
0.0 | 0.15 | 0.04 |
|
5yr CAGR Net Profit
|
6.67 % | 26.4 % | -9.63 % |
|
5yr Average Return on Assets
|
14.28 % | 9.87 % | 6.27 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
74.94 % | 32.68 % | 52.62 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-7.91 % | -3.54 % | 8.93 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.35 % | 6.87 % | 0.0 |
|
Alivus Life Sciences
|
Neuland Laboratories
|
IOL Chem & Pharma
|
|---|